Paraneoplastic Syndrome Market Research Report – Forecast to 2027

Paraneoplastic Syndrome Market Research Report:  By Type (Cutaneous Paraneoplastic Syndrome and Others), by Diagnosis (Blood Test, Spinal Tap, and Others), by Treatment (Medication and Others), by End User (Hospitals and Others)- Forecast till 2027

ID: MRFR/MED/5062-HCR | | Region: Global | 90 pages

Paraneoplastic Syndrome Market Scenario


The paraneoplastic syndrome market is expected to grow significantly over the forecast period.

A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically seen in the middle-aged population to older population. This syndrome mostly occurs with patients suffering from lung, ovarian, or breast cancers.  

Numerous factors are anticipated to drive the growth of this market such as the increasing prevalence of cancer, consumption of tobacco, unhealthy lifestyle, increasing geriatric population, and increasing occurrence of breast cancer, among women. According to the American Autoimmune Association, 50 million people suffered from autoimmune disorders in the US in 2017.  

Increasing collaborations among various research institutes for the development of novel diagnostic techniques for the diagnosis of the paraneoplastic syndrome are expected to drive the growth of this market.

Despite the drivers, factors such as unfavorable reimbursement scenario and stringent regulatory policies may hamper the growth of the market during the assessment period.

Segmentation

The paraneoplastic syndrome market has been segmented into types, diagnosis, treatment, and end users. Based on types, the market is segmented into cutaneous paraneoplastic syndrome, gastro-intestinal paraneoplastic syndrome, endocrine paraneoplastic syndrome, hematologic paraneoplastic syndrome, renal paraneoplastic syndrome, rheumatologic paraneoplastic syndromes, and neurologic paraneoplastic syndrome.

The market on the basis of diagnosis has been segmented into blood test, spinal tap (lumbar puncture), and

imaging tests. Imaging tests are further sub-segmented into computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and PET plus CT.

The market, by treatment, has been segmented into medication and therapies. Medication is further sub-segmented into corticosteroids, immunosuppressants, anti-seizure medications, plasmapheresis, and intravenous immunoglobulin (IVIg). On the basis of therapy, the market is further sub-segmented into physical therapy and speech therapy.

Based on end-user, the market is segmented into hospitals and clinics, diagnostic centers, and ambulatory care centers.

Key players

Some of the key players in the global paraneoplastic syndrome market are Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation,

York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.

Regional Market Summary

Global Paraneoplastic Syndromes Market Share (%), by Region, 2018


Paraneoplastic Syndromes Market


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC)


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The paraneoplastic syndrome market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European paraneoplastic syndrome market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The paraneoplastic syndrome market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The paraneoplastic syndrome market in the Middle East and Africa has been segmented into the Middle East and Africa.


Geographically, the Americas is anticipated to dominate the global paraneoplastic syndrome market. The market growth in this region is attributed to the increasing geriatric population with the paraneoplastic disorder, investment in research and development, and technological advancements. However, increasing approval of novel neurological diagnosis tools in this region is boosting the market in this region.


Europe is expected to be the second largest market in the globe owing to the increasing number of geriatric populations, increasing government expenditure for autoimmune disorders, the presence of disposable income, and increasing consumption of tobacco in this region.


Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of paraneoplastic disorder and cancer-related problems in developing countries, increasing disposable income, and growing healthcare expenditure.


The Middle East and Africa is expected to account for the lowest market share in the global paraneoplastic syndrome market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.


Global Paraneoplastic Syndrome Market, by Types



  • Cutaneous Paraneoplastic Syndrome

  • Gastro-Intestinal Paraneoplastic Syndrome

  • Endocrine Paraneoplastic Syndrome

  • Hematologic Paraneoplastic Syndromes

  • Renal Paraneoplastic Syndrome

  • Rheumatologic Paraneoplastic Syndromes

  • Neurologic Paraneoplastic Syndrome


Global Paraneoplastic Syndrome Market, by Diagnosis



  • Blood test

  • Spinal tap (lumbar puncture)

  • Imaging tests

  • Computerized tomography (CT)

  • Magnetic resonance imaging (MRI)

  • Positron emission tomography (PET)

  • PET plus CT


Global Paraneoplastic Syndrome Market, by Treatment



  • Medication

  • Corticosteroids

  • Immunosuppressants

  • Anti-seizure medications

  • Medications to enhance nerve to muscle transmission

  • Plasmapheresis

  • Intravenous immunoglobulin (IVIg)

  • Therapies

  • Physical therapy

  • Speech therapy


Global Paraneoplastic Syndrome Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Ambulatory Care Centers


Global Paraneoplastic Syndrome Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific



  • Middle East & Africa



  • Middle East

  • Africa


Global Paraneoplastic Syndrome Market, by Key Players



  • Healthineers

  • Koninklijke Philips N.V.

  • General Electric Company

  • Esaote SpA

  • NeuroLogica Corporation

  • Masimo Corporation

  • York Instruments Ltd

  • Neusoft Medical Systems

  • Canon Medical Systems Corporation


Intended Audience



  • Hospitals and clinics

  • Laboratories and associations

  • Healthcare providers

  • Research institutes and academic centers

  • Government associations

  • Market research and consulting



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2018-2023:Substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Diagnosis, Treatment, and End users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.
  Key Market Opportunities

  • Increasing disposable income
  • Growing healthcare expenditure
  •   Key Market Drivers   Increasing collaborations among various research institutes for the development of novel diagnostic techniques for the diagnosis


    Frequently Asked Questions (FAQ) :


    Ambulatory care centers, diagnostic centers, and hospitals and clinics are the different end users of Paraneoplastic Syndrome Market.

    The Americas is expected to lead the Male Breast Cancer Market.

    Rising prevalence of cancer and unhealthy lifestyle is boosting market growth.

    Unfavourable reimbursement scenario may limit market growth.

    Leading players profiled in the Paraneoplastic Syndrome Market include Canon Medical Systems Corporation, Neusoft Medical Systems, York Instruments Ltd., Masimo Corporation, NeuroLogica Corporation, Esaote SpA, General Electric Company, Koninklijke Philips N.V., and Healthineers.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Paraneoplastic Syndrome Market, by Types

    6.1 Introduction

    6.2 Cutaneous Paraneoplastic Syndrome

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3 Gastro-Intestinal Paraneoplastic Syndrome

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4 Endocrine Paraneoplastic Syndrome

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5 Hematologic Paraneoplastic Syndromes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.6 Renal Paraneoplastic Syndrome

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.7 Rheumatologic Paraneoplastic Syndromes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.8 Neurologic Paraneoplastic Syndrome

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 7. Global Paraneoplastic Syndrome Market, by Diagnosis

    7.1 Introduction

    7.2 Blood test

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3 Spinal tap (lumbar puncture)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4 Imaging tests

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4.1 Computerized tomography (CT)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4.2 Magnetic resonance imaging (MRI)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4.3 Positron emission tomography (PET)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4.4 PET plus CT

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8. Global Paraneoplastic Syndrome Market, by Treatment

    8.1 Introduction

    8.2 Medication

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.2.1 Corticosteroids

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.2.2 Immunosuppressants

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.2.3 Anti-seizure medications

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.2.4 Medications to enhance nerve to muscle transmission

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.2.5 Plasmapheresis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.2.6 Intravenous immunoglobulin (IVIg)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Therapies

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3.1 Physical therapy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3.2 Speech therapy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 9. Global Paraneoplastic Syndrome Market, by End User

    9.1 Introduction

    9.2 Hospitals & Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.3 Diagnostic Centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.4 Ambulatory Care Centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 10. Global Paraneoplastic Syndrome Market , by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12. Company Profiles

    12.1 Healthineers

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Koninklijke Philips N.V

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 General Electric Company

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Esaote SpA

    12.4.1 Company Overview

    12.4.2 Product Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 NeuroLogica Corporation

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Masimo Corporation

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 York Instruments Ltd

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Neusoft Medical Systems

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Canon Medical Systems Corporation

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s Viewpoint

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Predictions for the Paraneoplastic Syndrome Industry

    Chapter 14. Appendix


    LIST OF TABLES

    Table 1 Global Paraneoplastic Syndrome Market Synopsis, 2020-2027

    Table 2 Global Paraneoplastic Syndrome Market Estimates and Forecast, 2020-2027

    (USD Million)

    Table 3 Global Paraneoplastic Syndrome Market, by Region, 2020-2027 (USD Million)

    Table 4 Global Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD Million)

    Table 5 Global Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027(USD Million)

    Table 6 Global Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 7 Global Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)

    Table 8 North America: Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD

    Million)

    Table 9 North America: Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027 (USD Million)

    Table 10 North America: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 11 North America: Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)

    Table 12 US: Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD Million)

    Table 13 US: Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027 (USD Million)

    Table 14 US: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 15 US: Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)

    Table 16 Canada: Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD Million)

    Table 17 Canada: Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027 (USD Million)

    Table 18 Canada: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 19 Canada: Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)

    Table 20 South America: Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD

    Million)

    Table 21 South America: Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027 (USD Million)

    Table 22 South America: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 23 South America: Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)

    Table 24 Europe: Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD Million)

    Table 25 Europe: Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027 (USD Million)

    Table 26 Europe: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 27 Europe: Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)

    Table 28 Western Europe: Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD

    Million)

    Table 29 Western Europe: Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027 (USD Million)

    Table 30 Western Europe: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 31 Western Europe: Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)

    Table 32 Eastern Europe: Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD

    Million)

    Table 33 Eastern Europe: Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027 (USD Million)

    Table 34 Eastern Europe: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 35 Eastern Europe: Paraneoplastic Syndrome Market, by End User, 2020-2027(USD Million)

    Table 36 Asia-Pacific: Paraneoplastic Syndrome Market, by Types, 2020-2027 (USD

    Million)

    Table 37 Asia-Pacific: Paraneoplastic Syndrome Market, by Diagnosis, 2020-2027 (USD Million)

    Table 38 Asia-Pacific: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 39 Asia-Pacific: Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)

    Table 40 Middle East & Africa: Paraneoplastic Syndrome Market, by Types, 2020-2027

    (USD Million)

    Table 41 Middle East & Africa: Paraneoplastic Syndrome Market, by Technology, 2020-2027 (USD Million)

    Table 42 Middle East & Africa: Paraneoplastic Syndrome Market, by Treatment, 2020-2027 (USD Million)

    Table 43 Middle East & Africa: Paraneoplastic Syndrome Market, by End User, 2020-2027 (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for the Global Paraneoplastic Syndrome Market Figure 3 Segmentation Market Dynamics for the Global Paraneoplastic Syndrome Market Figure 4 Global Paraneoplastic Syndrome Market Share, by Types, 2020

    Figure 5 Global Paraneoplastic Syndrome Market Share, by Diagnosis, 2020

    Figure 6 Global Paraneoplastic Syndrome Market Share, by Treatment, 2020

    Figure 7 Global Paraneoplastic Syndrome Market Share, by End User, 2020

    Figure 8 Global Paraneoplastic Syndrome Market Share, by Region, 2020

    Figure 9 North America: Paraneoplastic Syndrome Share, by Country, 2020

    Figure 10 Europe: Paraneoplastic Syndrome Share, by Country, 2020

    Figure 11 Asia-Pacific: Paraneoplastic Syndrome Share, by Country, 2020

    Figure 12 Middle East & Africa: Paraneoplastic Syndrome Share, by Country, 2020

    Figure 13 Global Paraneoplastic Syndrome Market: Company Share Analysis, 2020 (%)

    Figure 14 Healthineers.: Key Financials

    Figure 15 Healthineers.: Segmental Revenue

    Figure 16 Healthineers.: Geographical Revenue

    Figure 17 Koninklijke Philips N.V..: Key Financials

    Figure 18 Koninklijke Philips N.V..: Segmental Revenue

    Figure 19 Koninklijke Philips N.V..: Geographical Revenue

    Figure 20 General Electric Company.: Key Financials

    Figure 21 General Electric Company.: Segmental Revenue

    Figure 22 General Electric Company.: Geographical Revenue

    Figure 23 Esaote SpA: Key Financials

    Figure 24 Esaote SpA : Segmental Revenue

    Figure 25 Esaote SpA: Geographical Revenue

    Figure 26 NeuroLogica Corporation..: Key Financials

    Figure 27 NeuroLogica Corporation..: Segmental Revenue

    Figure 28 NeuroLogica Corporation... Geographical Revenue

    Figure 29 Masimo Corporation: Key Financials

    Figure 30 Masimo Corporation: Segmental Revenue

    Figure 31 Masimo Corporation: Geographical Revenue

    Figure 32 York Instruments Ltd: Key Financials

    Figure 33 York Instruments Ltd: Segmental Revenue

    Figure 34 York Instruments Ltd: Geographical Revenue

    Figure 35 Neusoft Medical Systems: Key Financials

    Figure 36 Neusoft Medical Systems: Segmental Revenue

    Figure 37 Neusoft Medical Systems: Geographical Revenue

    Figure 38 Canon Medical Systems Corporation: Key Financials

    Figure 39 Canon Medical Systems Corporation: Segmental Revenue

    Figure 40 Canon Medical Systems Corporation: Geographical Revenue